SER150
Diabetic Kidney Disease in Type 2 Diabetes
Phase 2Active
Key Facts
About Serodus
Serodus is a publicly traded biotech founded in 2001 with a clear mission to delay kidney failure in Type 2 Diabetes patients. Its strategy centers on two clinical-stage, small molecule candidates, SER150 and SER140, which employ different mechanisms to combat Diabetic Kidney Disease. The company is currently exploring strategic options for an acquisition of its pipeline, indicating a pivotal phase in its corporate development. Leadership includes seasoned industry veterans with a strong track record in founding and growing biopharmaceutical companies.
View full company profile